hsa-miR-4435: Hsa-mir-4435 is a miRNA that has been found to be dysregulated in various diseases, including breast cancer, lung adenocarcinoma, hepatocellular carcinoma, multiple sclerosis, diabetic retinopathy, and pregnancy complications [PMC8158160] [PMC7138293] [PMC8641180] [PMC9820840] [PMC8000127] [PMC8545528] [PMC8539647]. In breast cancer patients, dysregulation of hsa-mir-4435 has been associated with poor overall survival (OS) and higher metastatic potential [PMC8158160]. It has also been identified as a potential metastatic biomarker in breast cancer due to its higher expression in highly metastatic cell lines compared to low metastatic cell lines [PMC8158160]. In lung adenocarcinoma (LUAD), hsa-mir-4435 is part of a miRNA signature that can classify pathological stages of the disease and has similar classification ability as other combinations of miRNAs [PMC7138293]. In hepatocellular carcinoma (HCC), hsa-mir-4435 is co-expressed with other miRNAs involved in HCC development and progression [PMC9820840]. In multiple sclerosis (MS), hsa-mir-4435 is expressed specifically in B cells but not in lymphoblastoid cell lines (LCLs) and may play a role in the disease pathogenesis [PMC8000127]. Additionally, hsa-mir-4435 has been associated with diabetic retinopathy progression and its host gene MIR4435-2HG may regulate diabetic retinopathy-related genes through this miRNA's activity [PMC8545528]. Finally, during pregnancy, hsa-mir-4435 expression is deregulated and it may be involved in common gestational complications due to its association with other miRNAs implicated in pregnancy [PMC8539647].